3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Breast Neoplasms
5
Ovarian Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Healthy Participants
2
Endometrial Neoplasms
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumour
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Melanoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
1
Fallopian Tube Neoplasms
1
Chondrosarcoma
1
Advanced Solid Tumours
1
Advanced Solid Malignancy,
1
Advanced Solid Malignancy
1
Advanced Cancer
1
Interventions
adavosertib
5
durvalumab
3
Paclitaxel
3
olaparib
2
ceralasertib
2
Fluorouracil
2
Carboplatin
2
pembrolizumab
1
factor IX, factor VII, factor X, prothrombin drug combination
1
drug XX Z
1
danvatirsen
1
capivasertib
1
Rifampin
1
Pantoprazole
1
Omeprazole
1
Leucovorin
1
Itraconazole
1
Irinotecan
1
Injections
1
Gemcitabine
1
Doxorubicin
1
Cisplatin
1
AZD0156
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Advanced Solid Tumours
×
capivasertib
×
Clear all
NCT04742036
2022-08-19
Capivasertib China PK Study
AstraZeneca
Phase 1
Completed
16 enrolled